CDX2 and neoplasm: To address these questions, we investigated SATB2 expression in a large cohort comprising 1039 CRCs and correlated the results with histomorphologic and immunohistochemical (CRC subtypes, tumour budding activity, WHO grade, CDX2 expression) as well as clinicopathological parameters (pTNM/UICC staging, tumour localisation) and explored the prognostic relevance of SATB2 expression in uni- and multivariate survival analyses in the overall cohort as well as in specific subgroups.